Glaxo adds Unilever vet to board; Stada's Q1 profits plummet; J&J seeks ethics advice;

@FiercePharma: The FDA Is On A Quest To Rid DTC Drug Ads Of Confounding Fine Print. Forbes article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Billionaire supporter Paulson could help Teva twist Mylan's arm. Report | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) will add Unilever ($UL) vet Manvinder Singh Banga to its board as a non-executive director this September. Release

> Net profit for Germany's Stada dropped 39% in Q1. Report

> Hungarian pharma Richter reported a 61% leap in first-quarter net profit to 15 billion forints ($55.52 million). Report

> Swedish drugmaker Meda posted Q1 core operating profit above expectations on Wednesday and reiterated its outlook for 2015. More

> Johnson & Johnson ($JNJ) will become the first pharma company to formally seek advice from outside medical ethicists on "compassionate use" requests. Report

> German chemicals group BASF has agreed to sell parts of its pharmaceutical ingredients business to Swiss drug contract manufacturer Siegfried Holding for 270 million euros ($306 million), including assumed debt. More

Medical Device News

@FierceMedDev: ICYMI from FierceDiagnostics: Agilent acquires maker of software for diagnostics laboratories. Report | Follow @FierceMedDev

@VarunSaxena2: NIH says viral vector for delivering gene therapy to treat blindness shows promise, Wall Street less sure. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Theranos hired a former Clinton policy adviser as its top lawyer. Bloomberg story | Follow @EmilyWFierce

> Medtronic aims to push insertion of world's tiniest cardiac monitor into the physicians' office. More

> Startup Moximed gets $33M to gain FDA approval of early stage osteoarthritis knee implant. Article

Biotech News

@FierceBiotech: FierceBiotech Radio with Editas Medicine's Katrine Bosley. More | Follow @FierceBiotech

@JohnCFierce: So the operational word for biotech valuations now seems to be 'frothy.' We blew past frothy months ago and now are at 'dizzying.' | Follow @JohnCFierce

> Pfizer taps new R&D leaders as Gutiérrez-Ramos heads back into biotech. Report

> Atlas' new immuno-oncology biotech recruits an AstraZeneca vet to take the reins. Item

> AbbVie gets a 'breakthrough' for one of its top cancer drugs. Article

CRO News

> Biocon's planned CRO IPO could change the tone in India. Item

> Catalent boosts its profits despite some flat revenue. More

> AMRI swings to another loss despite big sales gains. Story

> Quintiles beefs up in bioanalytics ahead of Quest partnership. Article

> Parexel trims its ambitions after a flat quarter. Report

Vaccines News

> Themis rounds up new cash for Chikungunya jab's PhII. News

> Three universities using $1.55M NIH grant to track vaccine attitudes via Twitter. Item

> GSK's vaccine operating profit, margin dive on Novartis fold-in. Story

> Sanofi promises 7% vax sales growth for 2015, despite rocky Q1. Report

> City of Hope, Fortress Biotech form new company to ward off CMV. Article

Pharma Manufacturing News

> Biosimilar manufacturers form group to influence market in U.S. Item

> Hospira whacks first 100 jobs as it shutters Clayton, NC, plant. More

> BASF selling some APIs, three plants to Siegfried. Report

> FDA makes strides in inspection effort but challenges persist. Story

> Manufacturing moves pay off for AMRI. Article

Pharma Asia News

> China kicks press into high gear to knock down talk on higher drug prices. More

> Australia budget is a showdown on cancer drug funding, safety net reach. Report

> Taiwan device maker Apex invests in India and plans more. More

> Afghan battlefield clotting agent makes a comeback in Russia. Article

> Sumitomo Dainippon, Takeda call it quits on Japan Latuda agreement. Story

And Finally... The FDA has granted Roche ($RHHBY) a breakthrough therapy designation for prospect venetoclax for the treatment of people who have relapsed or refractory chronic lymphocytic leukemia (CLL) with a genetic abnormality. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.